{
  "id": 20769152,
  "title": "Novel CAR-T platform uses radiation-activated switch to destroy tumors more effectively",
  "url": "https://urgent.news/2026/11/19/novel-car-t-platform-uses-radiation-activated-switch-to-destroy",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-19T16:20:12.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-car-platform-destroy-tumors-effectively.html"
  },
  "original_language": "en",
  "account": "Engineers at the University of Chicago Medicine Comprehensive Cancer Center have developed a groundbreaking CAR T-cell platform capable of effectively eradicating tumors, even those resistant to traditional treatments. This innovative platform employs a radiation-activated switch that triggers the release of tumor necrosis factor (TNF), a potent inflammatory cytokine, within the tumor microenvironment (TME).\n\nIn solid tumors, the immunosuppressive TME prevents CAR T-cell entry and causes cells that enter to become exhausted. The novel platform overcomes these barriers by equipping engineered CAR T cells with a gene for TNF that only activates upon exposure to radiation. This targeted delivery system, reported in Nature Cancer, demonstrated greater tumor regression when combined with local radiation and standard CAR T cells versus either treatment alone or standard CAR T cells plus radiation.\n\nTumors are not mere masses of cancer cells but consist of a complex mixture of immune cells, blood vessels, and cancer-associated fibroblasts that create a supportive environment shielding cancer cells from immune attack. Conventional therapies like chemotherapy and radiotherapy often fail because they don't completely eliminate this support network, enabling surviving cells to regrow with TME assistance. Similarly, CAR T cells struggle to infiltrate and eliminate tumors due to the immunosuppressive TME.\n\nRadiation therapy also faces limitations, with patients often relapsing as irradiated tumors regrow or metastasize, and escalating radiation doses leading to severe toxicity. The novel TNF-releasing CAR T cells engineered by the researchers address these issues by releasing TNF in a controlled manner specifically within the tumor, even where CAR T cells cannot find their target. This approach not only kills tumor cells but also reshapes the TME by causing necrosis, damaging blood vessels, and activating inflammatory and antigen-presentation programs, making the tumor more visible to the immune system.",
  "summary": "Engineering patients' own immune cells to find and destroy cancer using chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of blood cancers. However, its use is limited in solid tumors because the immunosuppressive tumor microenvironment prevents CAR T-cell entry into the tumor and causes cells that enter to become exhausted.",
  "key_points": [
    "University of Chicago Medicine develops radiation-activated CAR T-cell platform",
    "TNF released in tumor microenvironment triggers tumor regression",
    "Combination therapy outperforms standard treatments alone"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}